Skip Navigation

University of California-San Diego: Dataset Details, ID=SRP048631

Maintenance notice: We are currently addressing issues with broken links due to recent major website changes. We apologize for any inconvenience and appreciate your patience. Please contact brittany.trottier@niehs.nih.gov for assistance.

Superfund Research Program

Detection and Models of Toxicant Exposure

Center Director: Robert H. Tukey
Grant Number: P42ES010337
Funding Period: 2000-2023
View this project in the NIH Research Portfolio Online Reporting Tools (RePORT)

Program Links

Connect with the Grant Recipients

Visit the grantee's eNewsletter page Visit the grantee's Instagram page Visit the grantee's Facebook page

Title: Intestinally-biased FXR agonism browns white adipose tissue preventing obesity and insulin resistance

Accession Number: SRP048631

Link to Dataset: https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP048631

Repository: Sequence Read Archive (SRA)

Data Type(s): Nucleotide Sequence

Experiment Type(s): Transcriptome analysis

Organism(s): Mus musculus

Summary: The distributed expression of bile acid (BA) sensor Farnesoid X receptor (FXR) has led to new therapies targeting cholesterol metabolism, triglyceride production, hepatic steatosis and biliary cholestasis. In contrast to the effects of system-wide drugs, we posited that selective activation of intestinal FXR might mimic the restricted bile acid response linked to feeding. Like systemic drugs, the gut-specific FXR agonist Fexaramine robustly induces enteric FGF15 leading to alterations in BA composition but does so without activating FXR target genes in the liver. Unlike systemic drugs, we find Fexaramine reduces diet-induced weight gain, body-wide inflammation and hepatic glucose production, while enhancing thermogenesis and browning of white adipose tissue. These pronounced metabolic improvements suggest tissue-restricted FXR activation as a new approach in the treatment of obesity and metabolic syndrome.

Publication(s) associated with this dataset:
  • Fang S, Suh J, Reilly SM, Yu E, Osborn O, Lackey D, Yoshihara E, Perino A, Jacinto S, Lukasheva Y, Atkins AR, Khvat A, Schnabl B, Yu RT, Brenner DA, Coulter S, Liddle C, Schoonjans K, Olefsky J, Saltiel AR, Downes M, Evans RM. 2015. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat Med 21(2):159-165. doi:10.1038/nm.3760 PMID:25559344 PMCID:PMC4320010
Back
to Top